Mitigation of gastrointestinal graft-versus-host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination

Saurabh Chhabra,¹ Aniko Szabo,²* Annelie Clurman,³* Katelynn McShane,⁴ Nicholas Waters,³ Daniel Eastwood,² Lisa Samanas,⁵ Teng Fei,⁶ Gabriel Armijo,³ Sameen Abedin,¹ Walter Longo,¹ Parameswaran Hari,¹ Mehdi Hamadani,¹ Nirav N. Shah,¹ Lyndsey Runaas,¹ James H. Jerkins,¹ Marcel van den Brink,² Jonathan U. Peled²# and William R. Drobyski¹#

Bone Marrow Transplant and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI; ²Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI; ³Department of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY; ⁴Cancer Center Clinical Trials Office, Medical College of Wisconsin, Milwaukee, WI; ⁵Department of Pharmacy, Froedtert Health, Milwaukee, WI; ⁶Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY and ⁷Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA

*AS and AC contributed equally as co-second authors.

#JUP and WRD contributed equally as co-senior authors.

Correspondence: S.CHHABRA - schhabra@mcw.edu W. DROBYSKI - wdrobysk@mcw.edu

https://doi.org/10.3324/haematol.2022.281309

SUPPLEMENTAL FIGURE LEGEND

Supplemental Figure 1: Multivariate analysis of taxonomic profiles between the tocilizumab and control cohorts. The Maaslin2 package was used to generate mixed-effects models to determine relationships between the microbial composition and patient metadata between the two centers. We considered all post-baseline samples day 0-26, retaining genus-level abundances for taxa present in > 5% of the samples with a relative abundance >0.002. Significance after Benjamini-Hochberg correction is indicated with transparency, and the effect size and direction are shown with size and color, respectively. Patient ID is included as a random effect. (A). Bivariate model shows taxonomic changes over time and by center; data in the "Center" column indicate taxonomic changes in the control cohort relative to the reference toci center. (B). Multivariate plot of the associations between per-sample antibiotic exposures, time, and center which highlight taxonomic shifts associated with antibiotic exposures. (C). Number (and percentage) of 19 toci and 38 control patients exposed to each antibiotic; antibiotic groups included in the multivariate model are indicated by the asterisks (**).

Supplemental Figure 1

A B

	Center	Time							Antib	iotics						Center	Time
Tyzzerella •		•	Veillonella -												•		
Turicibacter •		•	Terrisporobacter -														
Sporobacter •		•	Staphylococcus -														
Schaalia -		•	Schaalia -														•
Ruminococcus •		•	Ruthenibacterium -														
Rothia •			Ruminococcus -														•
Roseburia •		•	Roseburia -														•
Romboutsia •		•	Romboutsia -														
Oscillibacter •		•	Prevotella -														
Neglecta •		•	Pediococcus =														
Monoglobus •		•	Parasutterella -														
Mogibacterium •		•	Monoglobus -														
Longibaculum •		•	Megasphaera -														
Lachnoclostridium •			Lactococcus -			_											
Intestinibacter •		•	Lachnoclostridium -														•
Hungatella •		•	Gemmiger -														
Gemmiger •		•	Faecalicatena -														
Fusicatenibacter			Faecalibacterium -														
S Faecalibacterium		•	f_Ruminococcaceae =														
Faecalibacterium f_Ruminococcaceae			f_Lachnospiraceae •											•			•
f_Lachnospiraceae			Escherichia •														
			Erysipelatoclostridium -														
Eubacterium •			Enterococcus =														
Escherichia •	_	•	Eggerthella •														
Enterococcus •	_	•	Dorea -														•
Eggerthella			Dialister -														
Drancourtella •		_	Coprococcus -														
Dorea •		•	Collinsella -														
Dialister •			Clostridium -														
Coprococcus •		•	Caproiciproducens -														
Collinsella •		•	Blautia •														
Blautia •		•	Bacteroides =														
Bifidobacterium •		•	Asaccharobacter -														
Asaccharobacter •			Anaerostipes -														
Anaerostipes •		•	Anaerobutyricum -														•
Anaerobutyricum •		•	Alistipes -														
Agathobaculum •			Akkermansia -														
Actinomyces •			Agathobaculum -														
Absiella •		•										1					ţ
	wo)	dir		Men	Oime	wern.	10.14	oral	ciam.	210le	Hone	Cillins	320	done	riide	droit	Hr.
	control Para	meter	do	penem ce	lebime ce	, ₋₀ 0	ile optide	s andb	de Cilrin	Jazole otazo	he beg	icilin ⁵	intal ^o qui	ndone suffore		dicohort	
	, ara		c _o .			dhcor"	"cobp.	WO	rittle	0,				50	corr		
			•	.0001	Agen de directe de												
			•	.001						Pai	amet	er					
			D -1 -	.01					Ма	gnitud	le						
Relative Change	• ne	egative	P-value BH-corrected	.05				0	1 2	3 4		6					
neialive Change		sitive	DI I-COITECTED	above	.05				• •	• 4							
	,,	•							. •								

С

imipenem	carbapenem**	-	1 (2.6)
cephalexin	cephem**	-	1 (2.6)
ceftazidime	cephem**	-	1 (2.6)
azithromycin	macrolide	-	1 (2.6)
ampicillin	penicillins**	-	1 (2.6)
ceftriaxone	cephem**	-	2 (5.3)
penicillin	penicillins**	-	3 (7.9)
cefazolin	cephem**	-	5 (13.2)
dapsone	antibacterial(other)	1 (5.3)	-
amox/clav	penicillins**	1 (5.3)	-
meropenem	carbapenem**	1 (5.3)	2 (5.3)
cefuroxime	cephem**	1 (5.3)	2 (5.3)
aztreonam	monobactam**	1 (5.3)	3 (7.9)
linezolid	oxazolidone**	2 (10.5)	2 (5.3)
TMP/SMX	sulfonamide**	2 (10.5)	6 (15.8)
vancomycin(iv)	glycopeptide(iv)**	2 (10.5)	37 (97.4)
vancomycin(oral)	glycopeptide(oral)**	3 (15.8)	3 (7.9)
metronidazole	nitroimidazole**	3 (15.8)	4 (10.5)
cefepime	cefepime**	4 (21.1)	5 (13.2)
pip-tazo	piptazo**	4 (21.1)	19 (50)
ciprofloxacin	quinolone**	4 (21.1)	34 (89.5)
levofloxacin	quinolone**	16 (84.2)	3 (7.9)
Antibiotic	Group	toci	control

SUPPLEMENTAL TABLE 1. PATIENT CHARACTERISTICS OF TOCILIZUMAB TRIAL PATIENTS (N=29)

Variable

Age, median (range)	57 (24-66)
Sex (M/F)	16/13
Disease (n, %)	10/13
AML	15 (52)
CR1	10 (34)
CR2	
	4 (14)
Secondary AML, CR1	1 (3)
ALL, CR1	1 (3)
MDS	6 (21)
Myelofibrosis	5 (17)
CML	2 (7)
Donor Type (n, %)	
MRD	12 (41)
MUD	17 (59)
Preparative Regimen (n, %)	
Bu/CY	1 (3)
Flu/Bu4	25 (86)
Flu/Bu3	3 (10)
Graft Source (n, %)	
Peripheral Blood	29 (100)
Disease Risk Index (n, %)	
Intermediate	12 (41)
High	16 (55)
Very High	1 (3)
CMV Serostatus (n, %)	
Donor-/Recipient-	9 (31)
Donor+/Recipient-	1 (3)
Donor+/Recipient+	9 (31)
Donor-/Recipient+	10 (34)
HCT-CI, (n, %)	· ,
0-1	10 (34)
2	7 (24)
3	6 (21)
4-5	6 (21)
ABO match	13 (45)
ABO mismatch	16 (55)
Major	8 (28)
Minor	7 (24)
Bidirectional	1 (3)
KPS, median (range)	80 (70-100)
ixi o, inculan (Lange)	00 (70-100)

Median follow up of survivors (range), months

20.9 (14.6-29.6)

AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplasia; CML, chronic myelogenous leukemia; CR, Complete Remission; MRD, matched related donor; MUD, matched unrelated donor; BU, Busulfan; CY, Cyclophosphamide; Flu, Fludarabine; CMV, Cytomegalovirus; HCT-CI, Hematopoietic Cell Transplantation-Comorbidity Index

SUPPLEMENTAL TABLE 2. DEMOGRAPHIC CHARACTERISTICS OF THE TOCILIZUMAB SUBSET AND THE MSK CONTROL COHORT FOR MICROBIOME ANALYSIS

Characteristics	Total	Control	Toci*		
Patients (n)	57	38	19		
Age (median-range)	61.8 (24-74.7)	66.1 (27.6-74.7)	56 (24-64)		
Gender					
Female	22 (38.6)	12 (31.6)	10 (52.6)		
Male	35 (61.4)	26 (68.4)	9 (47.4)		
Diagnosis (n, %)					
ALL	3 (5.3)	2 (5.3)	1 (5.3)		
AML	33 (57.9)	23 (60.5)	10 (52.6)		
MDS	14 (24.6)	11 (28.9)	3 (15.8)		
MDS/MPN	2 (3.5)	0 (0.0)	2 (10.5)		
MPN	5 (8.8)	2 (5.3)	3 (15.8)		
Graft Source (n, %)					
PBSC	57 (100.0)	38 (100.0)	19 (100.0)		
Conditioning Regimen (n, %)				
BU/CY	1 (1.8)	0 (0.0)	1 (5.3)		
Flu/BU3	3 (5.3)	0 (0.0)	3 (15.8)		
Flu/BU4	53 (93.0)	38 (100.0)	15 (78.9)		

^{*}Subset of the Toci patient cohort that had a pre-transplant and at least one post-transplant stool sample that were both successfully sequenced.

AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplasia; MPN, myeloproliferative disorder; MRD, matched related donor; PBSC, peripheral blood stem cells